Synthesis and biological activity of DNA damaging agents that form decoy binding sites for the estrogen receptor.

It is a goal of cancer chemotherapy to achieve the selective killing of tumor cells while minimizing toxicity to normal tissues. We describe the design of selective toxins forming DNA adducts that attract the estrogen receptor (ER), a transcription factor that is overexpressed in many human breast and ovarian tumors. The compounds consist of 4-(3-aminopropyl)-N,N-(2-chloroethyl)-aniline linked to 2-(4'-hydroxyphenyl)-3-methyl-5-hydroxy-indole. The former moiety is a DNA damaging nitrogen mustard and the latter is a ligand for the ER. The connection between these groups was refined to permit DNA adducts formed by the mustard portion of the molecule to present the ligand domain so that it was able to interact efficiently with the ER. By using 16-mers containing specific DNA adducts, it was determined that monoadducts and putative intrastrand crosslinks were preferred targets for the ER over interstrand crosslinks. A series of structurally related 2-phenylindole mustards was prepared, some of which were selectively toxic to the ER-positive breast cancer cell line MCF-7, as compared with the ER(-) negative line MDA-MB231. The ability both to bind to DNA and to interact significantly with the ER were essential to achieve selective lethality toward ER(+) cells. Compounds forming DNA adducts without the ability to bind receptor showed similar toxicities in the two cell lines. Several models could explain the selective toxicity of the mustard-phenylindole compounds toward ER(+) cells. The favored model suggests that a mustard-DNA adduct is shielded by the ER from DNA repair enzymes and hence cells possessing an abundance of the ER selectively retain the adduct and are killed.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  S. Lippard,et al.  The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. , 1996, Mutation research.

[3]  G. Eisenbrand,et al.  Synthesis of novel androgen-linked phosphoramide mustard prodrugs and growth-inhibitory activity in human breast cancer cells. , 1995, Anti-cancer drug design.

[4]  D. Crothers,et al.  Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA. , 1995, Biochemistry.

[5]  B. Katzenellenbogen,et al.  Antiestrogens: Mechanisms and actions in target cells , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  K. Powell,et al.  Binding of the transcription factor, Sp1, to non-target sites in DNA modified by benzo[a]pyrene diol epoxide. , 1995, Carcinogenesis.

[7]  G. Chu,et al.  A novel role for DNA photolyase: binding to DNA damaged by drugs is associated with enhanced cytotoxicity in Saccharomyces cerevisiae. , 1994, Molecular and cellular biology.

[8]  S. Lippard,et al.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. K. Treiber,et al.  Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S R Cherry,et al.  An unnatural biopolymer. , 1993, Science.

[11]  R. Tarone,et al.  Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. , 1993, Cancer research.

[12]  S. Lippard,et al.  Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.

[13]  J. Van De Sande,et al.  Uracil-DNA glycosylase as a probe for protein--DNA interactions. , 1993, Nucleic acids research.

[14]  L. McLaughlin,et al.  Covalent structure of a nitrogen mustard-induced DNA interstrand cross-link: an N7-to-N7 linkage of deoxyguanosine residues at the duplex sequence 5'-d(GNC) , 1993 .

[15]  S. Lippard,et al.  Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. , 1992, Science.

[16]  Masahiko S. Satoh,et al.  Role of poly(ADP-ribose) formation in DNA repair , 1992, Nature.

[17]  D. Housman,et al.  Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[18]  W. Denny,et al.  DNA-directed alkylating agents. 3. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the length of the linker chain. , 1990, Journal of medicinal chemistry.

[19]  D. K. Treiber,et al.  Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. , 1990, Biochemistry.

[20]  R. Pieper,et al.  Transcription-terminating lesions induced by bifunctional alkylating agents in vitro. , 1989, Carcinogenesis.

[21]  P. Chambon,et al.  The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. , 1989, The EMBO journal.

[22]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[23]  B. Slotman,et al.  Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. , 1988, Anticancer research.

[24]  G. Goldenberg,et al.  Estrogen receptor-binding affinity and cytotoxic activity of three new estrogen-nitrosourea conjugates in human breast cancer cell lines in vitro. , 1987, Cancer treatment reports.

[25]  V. Jordan,et al.  Structure-activity relationships of estrogens. , 1985, Environmental health perspectives.

[26]  E von Angerer,et al.  2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat. , 1984, Journal of medicinal chemistry.

[27]  W. Schuette,et al.  Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. , 1984, Cancer research.

[28]  A. Riggs,et al.  Lac repressor binding to non-operator DNA: detailed studies and a comparison of eequilibrium and rate competition methods. , 1972, Journal of molecular biology.

[29]  S. Korenman Relation Between Estrogen Inhibitory Activity and Binding to Cytosol of Rabbit and Human Uterus , 1970 .

[30]  M. Fernö,et al.  Estrogen and Progesterone Receptor Analyses in More Than 4000 Human Breast Cancer Samples: A Study with Special Reference to Age at diagnosis and stability of analyses , 1990 .

[31]  H. Sambrook Molecular cloning : a laboratory manual. Cold Spring Harbor, NY , 1989 .

[32]  W. Gilbert,et al.  Sequencing end-labeled DNA with base-specific chemical cleavages. , 1980, Methods in enzymology.

[33]  B. Singer The chemical effects of nucleic acid alkylation and their relation to mutagenesis and carcinogenesis. , 1975, Progress in nucleic acid research and molecular biology.

[34]  Lawley Pd Effects of Some Chemical Mutagens and Carcinogens on Nucleic Acids , 1966 .